-
Recbio and Rongsheng Biotech Join Forces to Develop New Adjuvant Vaccine Technologies
•
Jiangsu Recbio Technology Co., Ltd (HKG: 2179) and Shanghai Rongsheng Biotech Co., Ltd have announced a strategic partnership aimed at the joint development of innovative adjuvant vaccine technologies. The collaborative project, headquartered in Shanghai, will see Recbio contribute its independently developed new adjuvant based on their proprietary adjuvant technology platform.…
-
Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine
•
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a strategic licensing and partnership agreement with Saudi Arabian pharmaceutical firm SPIMACO. The agreement pertains to Recbio’s recombinant 9-valent human papillomavirus (HPV) vaccine, REC603. Under the terms of the deal, SPIMACO will secure exclusive rights to…
-
Jiangsu Recbio’s REC610 Shingles Vaccine Shows Positive Results in First-In-Human Study
•
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a Chinese biotechnology company, has announced positive results from the first-in-human (FIH) study for its novel adjuvanted recombinant shingles vaccine, REC610, which is being conducted in the Philippines. The study uses GlaxoSmithKline’s Shingrix (recombinant zoster vaccine; RZV), a major UK pharmaceutical company’s shingles…
-
Jiangsu Recbio and Yikang Biological Partner to Develop RSV Preventative Vaccine
•
Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development cooperation agreement with Yikang Biological (Suzhou) Co., Ltd to develop a recombinant respiratory syncytial virus (RSV) vaccine aimed at preventing RSV-induced respiratory diseases. Under the terms of the agreement, Yikang will contribute its self-designed RSV…
